What this study is
Background:
The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.
Objective:
This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA.
Eligibility:
Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol
Design
Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
Study details
- Official title
- Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
- Sponsor
- National Cancer Institute (NCI)
- Conditions
- Melanoma · Adenocarcinoma · Carcinoma NOS · Neuroendocrine Tumors
- Enrolling
- 1,150 people
- Starts
- 2009-06-15
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age greater than or equal to 18 years.
- Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).
- For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
You can't join if
- For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openNational Institutes of Health Clinical Center
Bethesda, Maryland, United States
Study team
Sponsor
National Cancer Institute (NCI)
Study ID 090161
Principal investigator
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.